Cargando...
Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion
Lenvatinib is a novel multikinase inhibitor that has recently shown antitumor activity against hepatocellular carcinoma (HCC) in a phase III trial. We report the case of a woman in whom lenvatinib showed long‐term antitumor activity, and in whom computed tomography (CT) scans revealed a series of su...
Guardado en:
| Publicado en: | Hepatol Res |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6850300/ https://ncbi.nlm.nih.gov/pubmed/30499247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hepr.13294 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|